For patients with non‐small cell lung cancer (NSCLC), testing for genetic alterations with prognostic and/or predictive significance is recommended prior to treatment selection [2]; such alterations include mutations in the epidermal growth factor receptor (EGFR) gene and rearrangement in the anaplastic lymphoma kinase (ALK) gene, among others [3]. Here, ALK is linked to lung cancer.